technical trading for a while until all dust settles. i bought some more this morning, not sure what monday will bring...hopefully celg will bounce off the 200 day ma and range bound from there until the so called market correction is over (hoping, wishing)....i mean market correction should not be a concern as people are still taking medicines regardless
We continue to rate Celgene Outperform, with a target price of $214. We believe that the market’s concern about Revlimid’s patent protection and NICE recommendations is overdone. We see no reason to change our revenue and earnings forecasts for the stock and recommend investors add to positions on this temporary weakness.